Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 351 to 375 of 890

TitleReference numberPublishedLast updated
Filgotinib for treating moderately to severely active ulcerative colitisTA792
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal)TA790
Romosozumab for treating severe osteoporosisTA791
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsTA789
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyTA788
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapiesTA786
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA787
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancerTA784
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal)TA785
Daratumumab monotherapy for treating relapsed and refractory multiple myelomaTA783
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerTA781
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal)TA782
Nivolumab with ipilimumab for untreated advanced renal cell carcinomaTA780
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiencyTA779
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoeaTA777
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuriaTA778
Empagliflozin for treating chronic heart failure with reduced ejection fractionTA773
Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal)TA774
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoeaTA776
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapiesTA772
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)TA771
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitableTA763
Fremanezumab for preventing migraineTA764
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA765

Results per page

  1. 10
  2. 25
  3. 50
  4. All